The Clinical Research of Low Intensity Continuous Ultrasonic on Lower Limb Arteriosclerosis Occlusion(ASO) Syndrome

Overview

In the present study, by evaluating the efficacy and safety of low intensity ultrasonic on ASO, to explore the noninvasive auxiliary treatment of ASO. 90 patients were randomly divided into 2 groups: A)control group, patients were given Conventional conservative treatment; B)treatment group, patients were given Conventional conservative treatment and low intensity ultrasonic treatment ; Treatments last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues; outcome indicators were recorded Before and 4 weeks after the trial, The Walking Impairment Questionnaire (WIQ), ankle brachial ratio, the farthest distance Walking, percutaneous tissue oxygen tension, tissue oxygenation index recovery time, local skin temperature, ultrasonic blood vessels, and muscle enzymes, hepatic and kidney function.

Full Title of Study: “The Clinical Research of Low Intensity Continuous Ultrasonic on Lower Limb Arteriosclerosis Occlusion(ASO) Syndrome”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2018

Detailed Description

Ultrasound is a form of sound whose frequency is higher than the natural audible range for humans (> 20 kHz) and ultrasonography has been widely used as diagnostic devices for several decades. In addition to diagnostic purposes, ultrasound is clinically used for therapeutic applications, including tumor ablation, thrombolysis, bone regeneration, and facilitated drug delivery. Recently, therapeutic angiogenic effects of low-intensity ultrasound have been reported in endothelial cells, chick chorioallantoic membrane, and a rat model of hind limb ischemia. the investigators hypothesis low-intensity ultrasound can improve the ailment of ASO. In the present study, by evaluating the efficacy and safety of low intensity ultrasonic on ASO, to explore the noninvasive auxiliary treatment of ASO. 90 patients were randomly divided into 2 groups: A)control group,patients were given Conventional conservative treatment: B)treatment group,patients were given Conventional conservative treatment and low intensity ultrasonic treatment; Treatments last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues;outcome indicators were recorded Before and 4 weeks after the trial, The Walking Impairment Questionnaire (WIQ), ankle brachial ratio, the farthest distance Walking, percutaneous tissue oxygen tension, tissue oxygenation index recovery time, local skin temperature, ultrasonic blood vessels, and muscle enzymes, hepatic and kidney function.

the investigators speculate after 4 weeks of Low intensity ultrasonic treatment, all the observation index of ASO patients can be improved; meanwhile, creatine kinase, liver and kidney function, blood in urine routine, electrocardiogram (ecg) has no obvious change.

Interventions

  • Other: Conventional conservative treatment
    • Treatment last for 4 weeks, three times a week,
  • Device: therapeutic ultrasound
    • Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues;

Arms, Groups and Cohorts

  • Experimental: control group
    • patients were given Conventional conservative treatment;
  • Experimental: therapeutic ultrasound group
    • patients were given Conventional conservative treatment and low intensity ultrasonic treatment ;

Clinical Trial Outcome Measures

Primary Measures

  • Improvement of ankle brachial ratio at 4 weeks of treatment
    • Time Frame: 4weeks

Secondary Measures

  • Improvement of local skin temperature at 4 weeks of treatment
    • Time Frame: 4weeks
  • Recovery of ultrasonic blood vessels at 4 weeks of treatment
    • Time Frame: 4weeks
  • Enhancement of the value of muscle enzymes at 4 weeks of treatment
    • Time Frame: 4weeks
  • Elevation of the value of hepatic and kidney function at 4 weeks of treatment
    • Time Frame: 4weeks
  • Improvement of the farthest distance Walking at 4 weeks of treatment
    • Time Frame: 4weeks
  • Changes of percutaneous tissue oxygen tension at 4 weeks of treatment
    • Time Frame: 4weeks

Participating in This Clinical Trial

Inclusion Criteria

  • lower limb arteriosclerosis occlusion disorder patients
  • In line with the Fontaine II – Ⅲ period clinical stage
  • Aged 35 to 70 years old
  • No major organ dysfunction, including heart, liver and kidney
  • Can understand the procedures and methods of the test, strictly observe clinical trial plan to complete the test, and sign the informed consent

Exclusion Criteria

  • Fontaine clinical staging in patients with stage I
  • Aged under 35 or more than 70 – year – old patient
  • Women with pregnancy or lactation
  • Childless and one year plan pregnancy
  • Patients with cardiac pacemaker
  • Patients with malignant tumor, psychosis
  • Accompanied by severe heart, brain, kidney and hematopoietic system disease
  • The following appeared in the process of being test: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass grafts, heart failure, cerebrovascular accident (including transient ischemic attack); And epilepsy, severe liver and kidney function is not complete, mechanical intestinal obstruction, bradycardia, bronchial asthma and other diseases
  • Researchers think the patient has any problem that may cause the participants can't finish this research ,or any other situation of risk to participants

Gender Eligibility: All

Minimum Age: 35 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
  • Provider of Information About this Clinical Study
    • Principal Investigator: Junli Duan, Deputy director of the department of Gerontology – Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.